Topiramate

同義語： Topiramate, 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate, McN-4853, RWJ-17021, TPM

Topiramate is a sulfamate-substituted monosaccharide that has become a staple in the antiepileptic and migraine-prophylaxis markets. Unlike many older anticonvulsants, it was designed from the ground up—born from a deliberate search for compounds that could block seizure spread through multiple mechanisms. First approved in the mid-1990s, it has since earned a place in formularies worldwide, both as monotherapy and as an adjunct for partial-onset seizures, and later for preventing migraines in adults.

Its chemical structure is built on a fructose scaffold, with a sulfamate group that sets it apart from other anticonvulsants. This unique architecture allows topiramate to act on several targets: voltage-gated sodium channels, GABA-A receptors, and AMPA/kainate glutamate receptors. That multi-pronged action is rare among neurological APIs and explains why it remains a focus for researchers exploring broader neurological applications.

For formulators, topiramate is a well-behaved crystalline solid, readily processed into tablets and sprinkle capsules. Its stability profile and compatibility with common excipients make it a reliable choice for both generic and branded products. While it is not a first-line treatment for every patient, its broad efficacy keeps demand steady across North America, Europe, and Asia.

機能

• Anticonvulsant activity: Blocks voltage-gated sodium channels and enhances GABA-mediated inhibition, reducing seizure frequency.
• Migraine prophylaxis: Modulates cortical spreading depression and glutamatergic transmission, lowering migraine attack frequency.
• Glutamate antagonism: Inhibits AMPA and kainate receptors, dampening excitatory neurotransmission.
• Carbonic anhydrase inhibition: Weakly inhibits carbonic anhydrase, contributing to its metabolic effects and side‑effect profile.

Source & Standardization

• 出典: Synthetic chemical synthesis
• Standardization: USP/EP/BP compliant; assay 98.0%–102.0% (HPLC)
• Forms: White to off-white crystalline powder
• 用途: Epilepsy, migraine prophylaxis, and investigational uses in neurology and psychiatry

仕様

資料・供給

• 月間処理能力: 10 metric tons
• リードタイム: 3～5営業日（在庫品）
• ドキュメント: COA, MSDS, TDS, and regulatory support available upon request
• パッケージ: 25 kg fiber drum with double polyethylene liners, or as per customer requirements

見積依頼

• リブバイオ株式会社. — メールアドレス： info@lyvbio.com